Supplemental Figure 2 from Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in &lt;i&gt;EGFR&lt;/i&gt;-Mutant Lung Cancer